疫苗经济评估中纳入更广泛价值指标的情况与影响
本综述审查了2014至2019年全球健康负担最大疫苗的成本效果分析,发现仅40%研究纳入至少一类社会影响,非健康部门影响极少被考虑。HPV疫苗案例显示,纳入非健康成本可使成本效果改善最高达90%或使疫苗具成本节约性。
要点
- 仅40%疫苗成本效果分析纳入至少一类社会影响,非健康部门影响纳入不足3%。
- 每QALY研究最常纳入生产力成本(25%),每DALY研究最常报告交通成本(24%)。
- HPV疫苗案例中纳入非健康成本可改善成本效果最高达90%或实现成本节约。
核心结论
- 少数疫苗成本效果分析纳入社会影响,尤其非健康部门影响常被忽略,可能导致社会视角下疫苗价值被系统性低估。
研究设计与样本
- 综述基于Tufts CEA注册库和Tufts全球健康CEA注册库,审查2014至2019年与全球健康负担最大疫苗相关的成本效果分析,并补充系统检索已发表和灰色文献。
- 共识别475项相关健康经济评估,开展描述性分析考察社会因素纳入频率及研究特征,并以HPV疫苗为例进行案例研究。
主要发现
- 总体40%研究纳入至少一类社会影响。
- 每QALY研究中非医疗成本最常纳入生产力(25%),每DALY研究中最常报告交通成本(24%)。
- 考察疫苗对教育、住房等其他部门影响的研究不足3%。
- 中等收入国家和北美地区与社会影响纳入正相关,撒哈拉以南非洲地区呈负相关。
- HPV案例中,纳入非健康成本使成本效果改善最高达90%或使疫苗具成本节约性,成本节约情景每避免一例宫颈癌节省最高达30,000美元。
临床怎么用
- 在疫苗经济评估中应考虑纳入生产力、交通等非健康成本及教育、住房等非健康部门影响,以更全面反映疫苗社会价值。
- 政策制定者参考成本效果分析时需注意社会影响纳入不足可能导致的疫苗价值低估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The health and economic benefits of immunization may extend beyond the elements traditionally included in cost-effectiveness analyses (CEAs). This review investigated how broader impacts are considered in economic evaluations of vaccines and whether their inclusion would substantially change CEA findings. METHODS: We reviewed CEAs of vaccines associated with the largest global health burden, published from 2014 to 2019 using the Tufts CEA Registry and Tufts Global Health CEA Registry. We supplemented this with a systematic review of published and grey literature. We conducted descriptive analyses to examine the frequency of inclusion of specific social factors and study characteristics associated with their inclusion. We also conducted a case study of the human papilloma virus (HPV) vaccine to illustrate the potential change in CEA findings from selected social impacts. RESULTS: We identified 475 relevant health economic assessments. Overall, 40% of studies included at least one category of social impact. The most commonly included non-healthcare cost among cost-per-QALY studies was productivity (25%), while cost-per-DALY studies reported transportation costs most frequently (24%). Few studies examined the impact of vaccination on other sectors such as education and housing (<3%). Middle-income and North American settings were positively associated with social impact inclusion, while sub-Saharan African location was negatively associated. In the HPV case study, the addition of nonhealth costs improved cost-effectiveness by up to 90% or made the vaccine cost-saving, depending on geographic setting. The cost-saving scenario saved up to $30,000 in costs per case of cervical cancer averted. CONCLUSIONS: A minority of vaccine CEAs include social impacts, particularly for nonhealth sectors. The omission of these impacts may result in a systematic undervaluation of vaccines from a societal perspective. Further efforts are required to document the full benefits of vaccination for policymaker consideration.
引用
- Silver MC, Neumann PJ, Ma S, et al. Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. Vaccine. 2021. PMID: 34656380. doi:10.1016/j.vaccine.2021.09.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。